LOGIN  |  REGISTER
Viking Therapeutics
Terns Pharmaceuticals

Gritstone bio to Participate in Upcoming Investor Conferences

June 01, 2023 | Last Trade: US$0.03 0.00 0.00

EMERYVILLE, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor conferences:

Goldman Sachs 44th Annual Healthcare Conference (Fireside Chat)
Fireside Chat Date and Time: Monday, June 12 at 4:00pm PT
Speaker: Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer
Location: Dana Point, CA
Webcast: https://cc.webcasts.com/gold006/061223a_js/?entity=46_YF42184

SVB Securities Therapeutics Forum (1x1s)
Conference Dates: July 11-12, 2023
Location: New York, NY

The live webcast will also be available via https://ir.gritstonebio.com/investors/events. An archived replay will be accessible for 30 days following the event.

About Gritstone bio

Gritstone is working to create the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets and have programs in viral diseases and solid tumors. Independently and with our partners, we are advancing a portfolio of product candidates with the aim of improving patient outcomes and eliminating disease. www.gritstonebio.com

Gritstone Contacts
Investors:
George E. MacDougall
Director, Investor Relations & Corporate Communications
Gritstone bio, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media:
Dan Budwick
1AB
(973) 271-6085
This email address is being protected from spambots. You need JavaScript enabled to view it.


Viking Therapeutics

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page